Skip to main content
SpringerLink
Log in
Book cover

Hughes Syndrome pp 155–170Cite as

Primary Antiphospholipid Syndrome

  • Chapter

  • 742 Accesses

Conclusion

PAPS has emerged as an important disease entity. Depending on the organ systems involved, it can produce a highly variable clinical picture, with severity ranging from mild asymptomatic disease (often undiagnosed) to major life-threatening events. It may be regarded as the pure form of a condition which is also frequently seen in the context of other autoimmune diseases. In particular it is intricately linked to APS seen in the context of SLE; and these two variants of the condition appear to behave in a similar fashion. Defining PAPS provides us with the opportunity to study the disease in the absence of other co-morbid conditions such as SLE. Advances in our understanding of the pathogenesis of PAPS should facilitate the development of improved treatment and outlook for patients with all forms of the APS.

Keywords

  • Systemic Lupus Erythematosus
  • Connective Tissue Disease
  • Lupus Anticoagulant
  • Anticardiolipin Antibody
  • Recurrent Miscarriage

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (Canada)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (Canada)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (Canada)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (Canada)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Moore JE, Mohr CF. Biologically false positive serologic tests for syphilis, type incidence and cause. JAMA 1952;150:467–473.

    CAS  Google Scholar 

  2. Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation [review]. Prog Hemost Thromb 1972;1:75–95.

    PubMed  CAS  Google Scholar 

  3. Bowie WEJ, et al. Thrombosis in SLE despite circulation anticoagulant. J Clin Invest 1963;62:413–430.

    Google Scholar 

  4. Margolius A, Jackson DP, Ratnoff OD. Circulation anticoagulants: a study of 40 cases and a review of the literature. Medicine (Baltimore) 1961;40:145–202.

    PubMed  Google Scholar 

  5. Nilsson IM, et al. Intrauterine death and circulating anticoagulant (“antithromboplastin”). Acta Med Scand 1975;197;153–159.

    CrossRef  PubMed  CAS  Google Scholar 

  6. Firkin BG, Howard MA, Radford N. Possible relationship between lupus inhibitor and recurrent abortion in young women [letter]. Lancet 1980;2:366.

    CrossRef  PubMed  CAS  Google Scholar 

  7. Carreras LO, et al. Arterial thrombosis, intrauterine death and “lupus” antiocoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981;1:244–246.

    CrossRef  PubMed  CAS  Google Scholar 

  8. Yin ET, Gaston LW. Purification and kinetic studies on a circulating anticoagulant in a suspected case of lupus erythematosus. Thromb Diath Haemorrhag 1965;14:88–115.

    CAS  Google Scholar 

  9. Laurell AB, Nilsson IM. Hypergammaglobulinaemia, circulating anticoagulant and biologic false positive Wassermann reaction. J Lab Clin Med 1957;49:694–707.

    PubMed  CAS  Google Scholar 

  10. Harris EN, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983;2:1211–1214.

    CrossRef  PubMed  CAS  Google Scholar 

  11. Violi F, et al. Anticoagulant activity of anticardiolipin antibodies. Thromb Res 1986;44:543–547.

    CrossRef  PubMed  CAS  Google Scholar 

  12. Boey ML, et al. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J 1983;287:1021–1023.

    CAS  Google Scholar 

  13. Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J 1983;287:1088–1089.

    CrossRef  CAS  Google Scholar 

  14. Hughes GR. The anticardiolipin syndrome [editorial]. Clin Exp Rheumatol 1985;3:285–286.

    PubMed  CAS  Google Scholar 

  15. Harris EN, et al. Clinical and serological features of the ‘antiphospholipid syndrome’ (APS). B J Rheumatol 1987:19.

    Google Scholar 

  16. Mackworth-Young CG, David J, Louizou S, Walport MJ, et al. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder [abstract]. Ann Rheum Dis 1987:26:94.

    Google Scholar 

  17. Asherson RA. A ‘primary’ antiphospholipid syndrome? J Rheumatol 1988;15:1742–1746.

    PubMed  CAS  Google Scholar 

  18. Asherson RA, et al. The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989;68;366–374.

    PubMed  CAS  Google Scholar 

  19. Mackworth-Young CG, Loizou S, Walport MJ. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis 1989;48:362–327.

    PubMed  CAS  Google Scholar 

  20. Alarcon-Segovia D, Sanchez-Guerrero J. Primary antiphospholipid syndrome [published erratum appears in J Rheumatol 1989;16:]. J Rheumatol 1989;16:482–428.

    PubMed  CAS  Google Scholar 

  21. Asherson RA, et al. Antiphospholipid syndrome: five year follow up. Ann Rheum Dis 1991;50:805–810.

    CrossRef  PubMed  CAS  Google Scholar 

  22. Mujic F, et al. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. J Rheumatol 1995;22:1589–1592.

    PubMed  CAS  Google Scholar 

  23. Andrews PA, Frampton G, Cameron JS. Antiphospholipid syndrome and systemic lupus erythematosus Lancet 1993;342:988–989.

    CrossRef  PubMed  CAS  Google Scholar 

  24. Vianna JL, et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am J Med 1994;96:3–9.

    CrossRef  PubMed  CAS  Google Scholar 

  25. Font J, et al. The ‘primary’ antiphospholipid syndrome: antiphospholipid antibody pattern and clinical features of a series of 23 patients. Autoimmunity 1991;9:69–75.

    CrossRef  PubMed  CAS  Google Scholar 

  26. Cervera R, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019–1027.

    CrossRef  PubMed  Google Scholar 

  27. Mackworth-Young CG. Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol 2004;136:393–401.

    CrossRef  PubMed  CAS  Google Scholar 

  28. Loizou CG, et al. Heterogeneity of binding reactivity to different phospholipids of antibodies from patients with systemic lupus erythematosus (SLE) and with syphilis. Clin Exp Immunol 1990;80:171–176.

    CrossRef  PubMed  CAS  Google Scholar 

  29. Galli M, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor [see comments]. Lancet 1990;33:1544–1547.

    CrossRef  Google Scholar 

  30. McNeil HP, et al. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990;87:4120–4124.

    CrossRef  PubMed  CAS  Google Scholar 

  31. Harris EN, Pierangeli S. Anticardiolipin antibodies: specificity and function. Lupus 1994;3:217–222.

    PubMed  CAS  Google Scholar 

  32. Matsuura E, et al. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994;179:457–462.

    CrossRef  PubMed  CAS  Google Scholar 

  33. Roubey RA, et al. “Anticardiolipin” autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995;154:954–960.

    PubMed  CAS  Google Scholar 

  34. Arvieux J, et al. Measurement of anti-phospholipid antibodies by ELISA using beta 2-glycoprotein I as an antigen. J Immunol Methods 1991;143:223–229.

    CrossRef  PubMed  CAS  Google Scholar 

  35. Roubey RA. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996;39:1444–1454.

    PubMed  CAS  Google Scholar 

  36. Giles IP, et al. How do antiphospholipid antibodies bind beta 2-glycoprotein 1? Arthritis Rheum 2003;48:2111–2121.

    CrossRef  PubMed  CAS  Google Scholar 

  37. Sorice M, et al. Anti-prothrombin but not “pure” anti-cardiolipin antibodies are associated with the clinical features of the antiphospholipid antibody syndrome. Thromb Haemost 1998;80:713–715.

    PubMed  CAS  Google Scholar 

  38. Nojima J, et al. Anti-prothrombin antibodies combined with lupus anti-coagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Br J Haematol 2001;114:647–654.

    CrossRef  PubMed  CAS  Google Scholar 

  39. Nojima J, et al. Acquired activated protein C resistance is associated with the co-existence of antiprothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol 2002;118:577–583.

    CrossRef  PubMed  CAS  Google Scholar 

  40. Pengo V, et al. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996;75:721–724.

    PubMed  CAS  Google Scholar 

  41. Forastiero RR, et al. Relationship of anti beta2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost 1997;78:1008–1014.

    PubMed  CAS  Google Scholar 

  42. Amengual O, Atsumi T, Koike T. Specificities, properties, and clinical significance of antiprothrombin antibodies. Arthritis Rheum 2003;48:886–895.

    CrossRef  PubMed  CAS  Google Scholar 

  43. Horbach DA, et al. The contribution of anti-prothrombin-antibodies to lupus anticoagulant activity—discrimination between functional and non-functional anti-prothrombin-antibodies. Thromb Haemost 1998;79:790–795.

    PubMed  CAS  Google Scholar 

  44. Galli M, et al. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1997;77:486–491.

    PubMed  CAS  Google Scholar 

  45. Horbach DA, et al. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996;76:916–924.

    PubMed  CAS  Google Scholar 

  46. Godeau B, et al. Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome. Br J Haematol 1997;98:873–879.

    CrossRef  PubMed  CAS  Google Scholar 

  47. Panzer S, et al. Specificities of platelet autoantibodies in patients with lupus anticoagulants in primary antiphospholipid syndrome. Ann Hematol 1997;74:239–242.

    CrossRef  PubMed  CAS  Google Scholar 

  48. Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995;22:-1899–1906.

    PubMed  CAS  Google Scholar 

  49. Kertesz Z, et al. Characterization of binding of human beta 2-glycoprotein I to cardiolipin. Biochem J 1995;310:315–321.

    PubMed  CAS  Google Scholar 

  50. Cabral AR, Cabiedes J, Alarcon-Segovia D. Antibodies to phospholipid-free beta 2-glycoprotein-I in patients with primary antiphospholipid syndrome. J Rheumatol 1995;22:1894–1898.

    PubMed  CAS  Google Scholar 

  51. Najmey SS, et al. The association of antibodies to beta 2 glycoprotein I with the antiphospholipid syndrome: a meta-analysis. Ann Clin Lab Sci 1997;27:41–46.

    PubMed  CAS  Google Scholar 

  52. Day HM, et al. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests. J Rheumatol 1998;25:667–674.

    PubMed  CAS  Google Scholar 

  53. Loizou S, et al. Association of quantitative anticardiolipin antibody levels with fetal loss and time of loss in systemic lupus erythematosus. Q J Med 1988;68:525–531.

    PubMed  CAS  Google Scholar 

  54. Escalante A, et al. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med 1995;98:559–565.

    CrossRef  PubMed  CAS  Google Scholar 

  55. Lopez-Soto A, et al. Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatidic acid, phosphatidylinositol and phosphatidylserine in systemic lupus erythematosus: prospective analysis of a series of 92 patients. Clin Exp Rheumatol 1997;15:143–149.

    PubMed  CAS  Google Scholar 

  56. Viard JP, Amoura Z, Bach JF. Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus [see comments]. Am J Med 1992;93:181–186.

    CrossRef  PubMed  CAS  Google Scholar 

  57. Levine SR, et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol 1995;38:119–124.

    CrossRef  PubMed  CAS  Google Scholar 

  58. Vaarala O, et al. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 1996;75:456–459.

    PubMed  CAS  Google Scholar 

  59. Alarcon-Segovia D, et al. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 1992;21:275–286.

    CrossRef  PubMed  CAS  Google Scholar 

  60. Cabral AR, et al. The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays. Am J Med 1996;101:472–481.

    CrossRef  PubMed  CAS  Google Scholar 

  61. Alarcon-Segovia D, et al. The antiphospholipid / cofactor syndromes. II. A variant in patients with systemic lupus erythematosus with antibodies to b2-glycoprotein I but no antibodies detectable in standard antiphospholipid assays. J Rheumatol 1997;24:1545–1551.

    PubMed  CAS  Google Scholar 

  62. Piette JC, et al. Systemic lupus erythematosus and the antiphospholipid syndrome: reflections about the relevance of ARA criteria [editorial] [see comments]. J Rheumatol 1992;19:1835–1837.

    PubMed  CAS  Google Scholar 

  63. Piette JC, et al. Exclusion criteria for primary antiphospholipid syndrome [letter]. J Rheumatol 1993;20:1802–1804.

    PubMed  CAS  Google Scholar 

  64. Johannsson EA, Niemi KM, Mustakillio KK. A peripheral vascular syndrome overlapping with SLE: recurrent venous thrombosis and hemorrhagic capillary proliferation with circulating anticoagulants and false-positive reactions for syphilis. Dermatologica 1977;15:257–267.

    Google Scholar 

  65. Alegre VA, Gastineau DA, Winkelmann RK. Skin lesions associated with circulating lupus anticoagulant. Br J Dermatol 1989;120:419–429.

    PubMed  CAS  Google Scholar 

  66. Asherson RA, Khamashta MA, Hughes GR. The hepatic complications of the antiphospholipid antibodies [editorial]. Clin Exp Rheumatol 1991;9:341–344.

    PubMed  CAS  Google Scholar 

  67. Pomeroy C, et al. Budd-Chiari syndrome in a patient with the lupus anticoagulant. Gastroenterology 1984;86:158–161.

    PubMed  CAS  Google Scholar 

  68. Mor F, et al. Hepatic infarction in a patient with the lupus anticoagulant. Arthritis Rheum 1989;32:491–495.

    PubMed  CAS  Google Scholar 

  69. Lee HJ, Park JW, Chang JC. Mesenteric and portal venous obstruction associated with primary antiphospholipid antibody syndrome. J Gastroenterol Hepatol 1997;12:822–826.

    PubMed  CAS  Google Scholar 

  70. Tatrai T, Kiss G, Sevcic K. [Inferior vena cava thrombosis developing in primary antiphospholipid syndrome]. Orv Hetil 1996;137:135–137.

    PubMed  CAS  Google Scholar 

  71. Asherson RA, George EN, Hughes GRV. Hypertension, renal artery stenosis and the ‘primary’ antiphospholipid syndrome. J Rheumatol 1991;18:1413–1415.

    PubMed  CAS  Google Scholar 

  72. Sonpal GM, Sharma A, Miller A. Primary antiphospholipid antibody syndrome, renal infarction and hypertension. J Rheumatol 1993;20:1221–1223.

    PubMed  CAS  Google Scholar 

  73. Grottolo A, et al. Primary adrenal insufficiency, circulating lupus anticoagulant and anticardiolipin antibodies in a patient with multiple abortions and recurrent thrombotic episodes. Haematologica 1988;73:517–519.

    PubMed  CAS  Google Scholar 

  74. Marie I, et al. Acute adrenal failure secondary to bilateral infarction of the adrenal glands as the first manifestation of primary antiphospholipid antibody syndrome [letter]. Ann Rheum Dis 1997;56:567–568.

    PubMed  CAS  Google Scholar 

  75. Takeuchi S, Obayashi T, Toyama J. Primary antiphospholipid syndrome with acute myocardial infarction recanalised by PTCA. Heart 1998;79:96–98.

    PubMed  CAS  Google Scholar 

  76. Nagai S, et al. Superior sagittal sinus thrombosis associated with primary antiphospholipid syndrome — case report. Neurol Med Chir 1998;38:34–39.

    CAS  Google Scholar 

  77. Sandoval J, et al. Primary antiphospholipid syndrome presenting as chronic thromboembolic pulmonary hypertension. Treatment with thromboendarterectomy. J Rheumatol 1996;23:772–775.

    PubMed  CAS  Google Scholar 

  78. Levine SR, et al. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990;40:1181–1189.

    PubMed  CAS  Google Scholar 

  79. Keller E, et al. [Coincident arterial and venous cerebral thrombosis in primary antiphospholipid syndrome]. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996;165:300–302.

    CrossRef  PubMed  CAS  Google Scholar 

  80. Khoo KB, et al. Cerebral venous sinus thrombosis associated with the primary antiphospholipid syndrome. Resolution with local thrombolytic therapy. Med J Aust 1995;162: 30–32.

    PubMed  CAS  Google Scholar 

  81. Badui E, et al. The heart in the primary antiphospholipid syndrome. Arch Med Res 1995;26:115–120.

    PubMed  CAS  Google Scholar 

  82. Coudray N, et al. M mode and Doppler echocardiographic assessment of left ventricular diastolic function in primary antiphospholipid syndrome. Br Heart J 1995;74:531–535.

    PubMed  CAS  Google Scholar 

  83. Hamsten A, et al. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986;1:113–116.

    CrossRef  PubMed  CAS  Google Scholar 

  84. Ames PR, et al. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 2004. In press.

    Google Scholar 

  85. APASS, The Antiphospholipid Antibodies in Stroke Study Group. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischaemia. Stroke 1990;21:1268–1273.

    Google Scholar 

  86. Montalban J, et al. Antiphospholipid antibodies in cerebral ischemia. Stroke 1991;22:750–753.

    PubMed  CAS  Google Scholar 

  87. Brey RL, et al. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990;40:1190–1196.

    PubMed  CAS  Google Scholar 

  88. APASS, The Antiphospholipid Antibodies in Stroke Study Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993;43:2069–2073.

    Google Scholar 

  89. Verrot D, et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997;103:33–37.

    CrossRef  PubMed  CAS  Google Scholar 

  90. Inzelberg R, Korczyn AD. Lupus anticoagulant and late onset seizures [see comments]. Acta Neurol Scand 1989;79:114–118.

    CrossRef  PubMed  CAS  Google Scholar 

  91. Sneddon IB. Cerebral vascular lesion in livedo reticularis. Br J Dermatol 1965;77:180–185.

    PubMed  CAS  Google Scholar 

  92. Kalashnikova LA, et al. Anticardiolipin antibodies in Sneddon’s syndrome. Neurology 1990;40:464–467.

    PubMed  CAS  Google Scholar 

  93. Asherson RA, et al. Systemic lupus erythematosus, antiphospholipid antibodies, chorea, and oral contraceptives [letter]. Arthritis Rheum 1986;29:1535–1536.

    PubMed  CAS  Google Scholar 

  94. Lubbe WF, Walker EB. Chorea gravidarum associated with circulating lupus anticoagulant: successful outcome of pregnancy with prednisone and aspirin therapy. Case report. Br J Obstet Gynaecol 1983;90:487–490.

    PubMed  CAS  Google Scholar 

  95. Goldstein SR. Embryonic death in early pregnancy: a new look at the first trimester. Obstet Gynecol 1994;84:294–297.

    PubMed  CAS  Google Scholar 

  96. Lockwood CJ, et al. Anti-phospholipid antibody and pregnancy wastage. Lancet 1986;2:742–743.

    CrossRef  PubMed  CAS  Google Scholar 

  97. Cowchock S, Smith JB, Gocial B. Antibodies to phospholipids and nuclear antigens in patients with repeated abortions. Am J Obstet Gynecol 1986;155:1002–1010.

    PubMed  CAS  Google Scholar 

  98. Unander AM, et al. Anticardiolipin antibodies and complement in ninety-nine women with habitual abortion. Am J Obstet Gynecol 1987;156l:114–119.

    Google Scholar 

  99. Petri M, et al. Antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody in women with idiopathic habitual abortion. A controlled, prospective study of forty-four women. Arthritis Rheum 1987;30:601–606.

    PubMed  CAS  Google Scholar 

  100. Granger KA, Farquharson RG. Obstetric outcome in antiphospholipid syndrome. Lupus 1997;6:509–513.

    PubMed  CAS  Google Scholar 

  101. Oshiro BT, et al. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996;87:489–493.

    CrossRef  PubMed  CAS  Google Scholar 

  102. Silver RM, et al. Anticardiolipin antibodies: clinical consequences of “low titers”. Obstet Gynecol 1996;87:494–500.

    CrossRef  PubMed  CAS  Google Scholar 

  103. Aoki K, et al. Specific antiphospholipid antibodies as a predictive variable in patients with recurrent pregnancy loss. Am J Reprod Immunol 1993;29:82–87.

    PubMed  CAS  Google Scholar 

  104. Derue G, et al. Foetal loss in systemic lupus: association with anticardiolipin antibodies. J Obstet Gynaecol 1985;5:207–209.

    Google Scholar 

  105. Fanelli A, et al. Flow cytometric detection of circulating activated platelets in primary antiphospholipid syndrome. Correlation with thrombocytopenia and anticardiolipin antibodies. Lupus 1997;6:261–267.

    PubMed  CAS  Google Scholar 

  106. Emmi L, et al. Possible pathogenetic role of activated platelets in the primary antiphospholipid syndrome involving the central nervous system. Ann N Y Acad Sci 1997;823:188–200.

    PubMed  CAS  Google Scholar 

  107. Silver RM, et al. Clinical consequences of antiphospholipid antibodies: an historic cohort study. Obstet Gynecol 1994;83:372–377.

    PubMed  CAS  Google Scholar 

  108. Vianna JL, et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients [see comments]. Am J Med 1994;96:3–9.

    CrossRef  PubMed  CAS  Google Scholar 

  109. Gattorno M, et al. Outcome of primary antiphospholipid syndrome in childhood. Lupus 2003;12:449–453.

    CrossRef  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cartilage Biology, Kennedy Institute of Rheumatology, London, UK

    Tonia L. Vincent MRCP, PhD

  2. Department of Rheumatology, Charing Cross Hospital, London, UK

    Charles G. Mackworth-Young MD, FRCP

Authors
  1. Tonia L. Vincent MRCP, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles G. Mackworth-Young MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lupus Research Unit, St Thomas’ Hospital, London, UK

    M. A. Khamashta MD, FRCP, PhD (Deputy Head) (Deputy Head)

Rights and permissions

Reprints and Permissions

Copyright information

© 2006 Springer-Verlag London Limited

About this chapter

Cite this chapter

Vincent, T.L., Mackworth-Young, C.G. (2006). Primary Antiphospholipid Syndrome. In: Khamashta, M.A. (eds) Hughes Syndrome. Springer, London. https://doi.org/10.1007/1-84628-009-5_15

Download citation

  • DOI: https://doi.org/10.1007/1-84628-009-5_15

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-873-2

  • Online ISBN: 978-1-84628-009-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

search

Navigation